Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders.

[1]  N. Niederle,et al.  Treatment of chronic myelogenous leukemia with different cytokines. , 1992, Seminars in oncology.

[2]  S. Seeber,et al.  A prospective randomized comparison of single‐agent interferon (IFN)‐alpha with the combination of IFN‐alpha and low‐dose IFN‐gamma in chronic myelogenous leukaemia , 1992, European journal of haematology.

[3]  R. Kurzrock,et al.  Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia , 1991, Cancer.

[4]  L. Rönnblom,et al.  Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. , 1991, Annals of internal medicine.

[5]  J. Smolen,et al.  Interferon-gamma induced exacerbation of systemic lupus erythematosus. , 1990, The Journal of rheumatology.

[6]  L. Rönnblom,et al.  Possible induction of systemic lupus erythematosus by interferon‐α treatment in a patient with a malignant carcinoid tumour , 1990, Journal of internal medicine.

[7]  M. Inbar,et al.  Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma. , 1990, European journal of cancer.

[8]  N. Niederle,et al.  TREATMENT OF ESSENTIAL THROMBOCYTHAEMIA WITH INTERFERON ALPHA-2b , 1989, The Lancet.

[9]  R. Figlin,et al.  Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Kirchner,et al.  Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? , 1988, Acta neurologica Scandinavica.

[11]  N. Niederle,et al.  Zur Dosierung von Interferon alpha in der Induktions und Erhaltungstherapie der Haarzellenleukämie , 1988 .

[12]  Goldie Jh,et al.  Impact of dose-intense chemotherapy on the development of permanent drug resistance. , 1987 .

[13]  M. Okamura,et al.  Serum levels of interferons in patients with systemic lupus erythematosus. , 1987, Clinical and experimental immunology.

[14]  W. Irving,et al.  Intradermal hepatitis B vaccine. , 1987, Lancet.

[15]  R. Hirsch,et al.  EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERON , 1987, The Lancet.

[16]  T. Tötterman,et al.  Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. , 1986, The Journal of clinical endocrinology and metabolism.

[17]  L. Akard,et al.  Alpha-interferon and immune hemolytic anemia. , 1986, Annals of internal medicine.

[18]  R. Kurzrock,et al.  Clinical toxicity of interferons in cancer patients: a review. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  B. Barlogie,et al.  Immune Thrombocytopenia Following α-Interferon Therapy in Patients With Cancer , 1985 .

[20]  P. Bevan.  INTERFERON-INDUCED PAROTITIS AND EPIDIDYMITIS , 1985, The Lancet.

[21]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[22]  E. Kreuzfelder,et al.  Vergleichende Untersuchungen zum Nachweis antinukleärer Antikörper (ANA) , 1981 .

[23]  C. M. Steel,et al.  Letter: Rosetting tests. , 1974, Lancet.